Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial.
Byeong-Zu GhangJi Sung LeeJihye ChoiJinseok KimBin YooPublished in: RMD open (2022)
MACE and CV death were increased in the initial stage after discontinuation of febuxostat or allopurinol in patients with gout.